tert-butyl 4-(5-chloro-3-((2-(diethylamino)ethyl)amino)-2-methylphenyl)piperazine-1-carboxylate | 1366472-99-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(5-chloro-3-((2-(diethylamino)ethyl)amino)-2-methylphenyl)piperazine-1-carboxylate
• CAS: 1366472-99-2
• 化学式: C₂₂H₃₇ClN₄O₂
• 分子量: 425.014
• InChiKey: UHDVXUPGXIRQBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.46
• 重原子数：
  29.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  48.05
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(5-chloro-3-((2-(diethylamino)ethyl)amino)-2-methylphenyl)piperazine-1-carboxylate 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 反应 0.03h， 生成 N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-diethylethane-1,2-diamine
  参考文献：
  名称：

  Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors

  摘要：

  The 70-kDa ribosomal protein S6 kinase (p70S6K) is part of the PI3K/AKT/mTOR pathway and has been implicated in cancer. High throughput screening versus p70S6K led to the identification of aminopyrimidine 3a as active inhibitor. Lead optimization of 3a resulted in highly potent, selective, and orally bioavailable pyrazolopyrimidines. In this manuscript we report the structure-activity relationship of this series and pharmacokinetic, pharmacodynamic, and efficacy data of the lead compound 13c. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.105
• 作为产物：
  描述：

  5-氯-3-碘-2-甲基苯胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二乙二醇二甲醚 为溶剂， 反应 44.0h， 生成 tert-butyl 4-(5-chloro-3-((2-(diethylamino)ethyl)amino)-2-methylphenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors

  摘要：

  The 70-kDa ribosomal protein S6 kinase (p70S6K) is part of the PI3K/AKT/mTOR pathway and has been implicated in cancer. High throughput screening versus p70S6K led to the identification of aminopyrimidine 3a as active inhibitor. Lead optimization of 3a resulted in highly potent, selective, and orally bioavailable pyrazolopyrimidines. In this manuscript we report the structure-activity relationship of this series and pharmacokinetic, pharmacodynamic, and efficacy data of the lead compound 13c. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.105